The JAK2 V617F gain-of-function mutation is the primary driver of Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Comprehensive evaluation of JAK2 V617F mouse disease models provides essential data on disease phenotype, progression, and therapeutic response for preclinical drug development. This article details the sample types, testing items, analytical methods, and applications involved in professional JAK2 V617F mouse model evaluation services.
Technical Overview
The JAK2 V617F mutation is a somatic point mutation (c.1849G>T) in exon 14 of the Janus kinase 2 gene, resulting in a valine-to-phenylalanine substitution at codon 617. This mutation abrogates the autoinhibitory function of the JH2 pseudokinase domain, leading to constitutive activation of JAK2 signaling and downstream STAT, MAPK, and PI3K pathways. The mutation is detected in approximately 95% of polycythemia vera (PV) patients and 50-60% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF).
Genetically engineered JAK2 V617F mouse models, including conditional knock-in models, transgenic models, and bone marrow transplantation models, faithfully recapitulate key features of human MPNs. Typical disease phenotypes include polycythemia, leukocytosis, thrombocytosis, marked splenomegaly, extramedullary hematopoiesis, and progressive myelofibrosis. Systematic evaluation of these models is critical for confirming disease establishment, monitoring disease progression, and quantifying pharmacological efficacy of candidate therapeutics such as JAK inhibitors.
A professional JAK2 V617F mouse disease model evaluation program integrates genotyping, hematology, histopathology, flow cytometry, molecular biology, and functional assays to deliver a complete phenotypic and mechanistic characterization of the model under study.
Testing Samples
Peripheral Blood
Peripheral blood is collected via tail vein, submandibular, or retro-orbital sampling at serial time points for longitudinal monitoring. It is used for complete blood counts, flow cytometric immunophenotyping, cytokine measurement, and circulating mutant allele burden analysis.
Bone Marrow Cells
Bone marrow is harvested from femurs and tibias for hematopoietic stem and progenitor cell (HSPC) analysis, colony-forming assays, mutant allele quantification, and signaling pathway studies in lineage-specific populations.
Spleen and Liver Tissues
Spleen and liver are collected at necropsy for organ weight measurement, histopathological examination of extramedullary hematopoiesis, reticulin and collagen fiber staining for fibrosis grading, and flow cytometric analysis of infiltrating hematopoietic populations.
Plasma and Serum
Plasma and serum samples are used for quantification of inflammatory cytokines, including IL-6, TNF-alpha, IL-1beta, and elevated inflammatory markers that correlate with systemic inflammation and constitutional symptoms observed in MPN patients.
Genomic DNA and RNA
Genomic DNA extracted from blood or sorted hematopoietic cells is used for genotyping and mutant allele burden quantification. Total RNA is prepared for gene expression profiling of JAK-STAT pathway targets such as PPR1V1 (Socs3), Mpl, and Gata1-related transcriptional programs.
Testing Items
- Genotype confirmation and JAK2 V617F mutant allele burden quantification
- Complete blood count including red blood cells, hematocrit, hemoglobin, white blood cell differential, and platelet counts
- Erythropoietin (EPO) serum concentration measurement
- Spleen weight to body weight ratio and liver weight index
- Histopathology of bone marrow, spleen, and liver with H&E staining
- Reticulin and Masson trichrome staining for myelofibrosis grading
- Flow cytometry immunophenotyping of hematopoietic stem cells, progenitors, and mature lineages
- Endogenous erythroid colony (EEC) formation assay for EPO-independent growth
- Colony-forming cell (CFC) assays in methylcellulose media
- Phospho-STAT3, phospho-STAT5, and phospho-ERK signaling analysis
- Inflammatory cytokine and chemokine profiling
- Survival analysis and disease progression monitoring
Testing Methods
Genotyping and allele burden are determined by allele-specific quantitative PCR using TaqMan probes or droplet digital PCR (ddPCR), which provides sensitive quantification of mutant-to-wild-type allele ratios. Sanger sequencing or next-generation sequencing is applied for confirmatory mutation analysis.
Hematological parameters are measured using automated veterinary hematology analyzers with species-specific calibration, enabling accurate quantification of red cell indices, leukocyte subsets, and platelet counts from small-volume samples.
Histopathological evaluation is performed on formalin-fixed, paraffin-embedded tissue sections stained with hematoxylin and eosin for morphology, Gordon-Sweets reticulin staining for fibrosis grading, and Masson trichrome for collagen deposition. Scoring is conducted according to established MPN fibrosis grading criteria.
Flow cytometric analysis employs multiparameter panels to quantify LSK cells, myeloid progenitor subsets, mature lineage populations, and activation markers using antibodies against c-Kit, Sca-1, lineage markers, CD34, FcR, CD150, CD41, Ter119, Gr-1, and Mac-1.
Signal transduction analysis is conducted by intracellular phospho-flow cytometry or Western blotting to measure phosphorylated STAT5, STAT3, and ERK levels following cytokine stimulation. Gene expression analysis is performed by quantitative RT-PCR or RNA sequencing.
Functional assessment includes endogenous erythroid colony assays in methylcellulose culture without exogenous erythropoietin, a hallmark functional readout of JAK2 V617F-driven erythropoietin hypersensitivity, together with standard BFU-E, CFU-GM, and CFU-MK colony assays.
Applications
- Efficacy evaluation of JAK inhibitors including ruxolitinib, fedratinib, and pacritinib in preclinical studies
- Assessment of novel targeted therapies such as type II JAK2 inhibitors, HSP90 inhibitors, and BET inhibitors
- Investigation of MPN disease mechanisms including clonal evolution, inflammation, and myelofibrosis progression
- Evaluation of combination treatment strategies with interferon, hypomethylating agents, or immunomodulatory drugs
- Biomarker discovery and pharmacodynamic marker validation for clinical translation
- Leukemic transformation studies modeling blast phase progression
- Comparative phenotype studies of JAK2 V617F homozygous versus heterozygous mutant genotypes
- Support for IND-enabling preclinical data packages for hematological drug candidates
FAQ
What disease phenotypes do JAK2 V617F knock-in mice display?
Heterozygous Jak2V617F knock-in mice typically develop a polycythemia vera-like phenotype with elevated hematocrit, splenomegaly, and low erythropoietin levels, while homozygous mutants more closely resemble primary myelofibrosis with severe anemia, marked splenomegaly, extramedullary hematopoiesis, and lethal myelofibrosis.
How is disease progression monitored longitudinally?
Disease progression is monitored through serial peripheral blood sampling for complete blood counts, periodic measurement of mutant allele burden by ddPCR, body weight tracking, and splenic volume assessment by ultrasound imaging, complemented by end-point histopathological analysis.
What are the key efficacy endpoints for drug evaluation studies?
Primary endpoints include reduction in hematocrit and white blood cell counts, spleen size normalization, improvement in myelofibrosis grade, reduction in phospho-STAT5 levels, decreased mutant allele burden, and improvement in survival compared with vehicle-treated controls.
How sensitive is ddPCR for detecting the JAK2 V617F mutant allele?
Droplet digital PCR can reliably detect mutant allele frequencies as low as 0.1%, making it suitable for minimal residual disease monitoring and sensitive quantification of allele burden dynamics during therapeutic intervention.
What study duration is typically required for model evaluation?
Baseline hematological abnormalities usually emerge within 4 to 8 weeks after inducible mutation activation or bone marrow transplantation. Short-term pharmacodynamic studies typically run 2 to 4 weeks, while efficacy and survival studies commonly extend from 8 weeks to more than 6 months depending on the therapeutic question.